| Original language | English (US) |
|---|---|
| Pages (from-to) | 495-496 |
| Number of pages | 2 |
| Journal | Gastroenterology |
| Volume | 164 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
FDA Draft Guidance for Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet : Comments by the Society for the Study of Celiac Disease. / SSCD Executive Council; SSCD Writing Committee.
In: Gastroenterology, Vol. 164, No. 3, 03.2023, p. 495-496.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - FDA Draft Guidance for Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet
T2 - Comments by the Society for the Study of Celiac Disease
AU - SSCD Executive Council
AU - SSCD Writing Committee
AU - Lebwohl, Benjamin
AU - Verma, Ritu
AU - Kelly, Ciaran
AU - Leffler, Daniel
AU - Weisbrod, Vanessa
AU - Roland Lee, Anne
AU - Leonard, Maureen
AU - Therrien, Amelie
AU - Adelman, Daniel
AU - Geller, Marilyn
AU - Murray, Joseph
N1 - Funding Information: Conflicts of interest These authors disclose the following: Dr Adelman has served as a consultant or advisor to Takeda, GSK, Anokion, Equillium, and Protagonist. Ms Geller served as a consultant for ICON. Dr Kelly has served as a consultant or advisor to Cour Pharma, Jansen (J&J), Kanyos/Anokion, Merck, Milky Way Life Sciences, Takeda, and Teravance; as an Investigator to Merck, Milky Way Life Sciences, and Takeda; and holds stock options in Cour Pharma and Glutenostix. Dr Leonard has served as a consultant to Mozart Therapeutics and Amgen Pharmaceuticals; as an advisory board member for 9 Meters Biopharma; and received research support from Glutenostics LLC. Dr Leffler is an employee of Takeda Pharmaceutical. Dr Murray reports grants from Nexpep/ImmusanT, Immunogenix, Takeda Pharmaceutical, Allakos, Provention Bio, Oberkotter Foundation, and Kanyos/Anokion; and consultancy fees from Johnson & Johnson, Bristol Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone Pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Kanyos, Alimentiv, Equillium, Ukko, and Vial Health Technologies; and has received royalties from Torax Medical and Evelo. The remaining authors disclose no conflicts.
PY - 2023/3
Y1 - 2023/3
UR - http://www.scopus.com/inward/record.url?scp=85147983837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147983837&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2022.07.024
DO - 10.1053/j.gastro.2022.07.024
M3 - Letter
C2 - 35863532
AN - SCOPUS:85147983837
SN - 0016-5085
VL - 164
SP - 495
EP - 496
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -